日中データの期間を指定してください。このエクスポートには2〜3分かかります。このタブを開いたままにすると、ダウンロードが自動的に始まります。
A detailed description of the company is not yet available....
2025年のVericelの売上高は276.26Mで、前年の237.22Mから16.45%の増加でした。 利益は16.52Mで、59.41%の増加でした。
7件のアナリスト評価によると、VCEL株の平均レーティングは「Strong Buy」です。12か月後の目標株価は59で、直近株価から33.48%の上昇余地となります。
MediWound (NASDAQ:MDWD) reported second-quarter 2026 revenue of $3.1 million, down from $5.7 million a year earlier, as the company continued investing in its Phase III EscharEx chronic-wound program ...
IPO Edge hosted a fireside chat with Conexeu Sciences Inc. (Nasdaq: CNXU) President and Chief Executive Officer Miles Harrison, moderated by IPO Edge Editor-in-Chief John Jannarone and Editor-at-Large...
Vericel (NASDAQ:VCEL) reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improve...
Vericel (VCEL) delivered earnings and revenue surprises of +200.00% and +7.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Focused on regenerative therapies for sports medicine and burn care, this biopharma firm reported a notable insider sale in June.